Brit J Cancer 1995;72:1278-82.Grosclaude P, Galat JP, Mace-Lesech J, Roumagnac-Macheleard M, Mercier M, Robillard J. Differences in treatment and survival rates of non-small cell lung cancer in three regions of France. Br J Cancer 1995; 72: 1278-82....
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screeni
CA Cancer J. Clin. 73, 17–48 (2023). Article PubMed Google Scholar Wang, Y. et al. Survival trends among patients with metastatic non-small cell lung cancer before and after the approval of immunotherapy in the United States: a Surveillance, Epidemiology, and End Results database-based...
8.2Non-small cell lung cancer PPM1D is upregulated in non-small cell lung cancer (NSCLC), the most common type of lung cancer, compared with normal lung tissue. High PPM1D expression was associated with inferior 6-year overall patient survival. Amultivariate analysisidentified tumor ...
Rades D, Douglas S, Veninga T, Schild SE (2012) A validated survival score for patients with metastatic spinal cord compression from non-small cell lung cancer. BMC Cancer 12:302 CentralRades D, Douglas S, Veninga T, Schild SE. A validated survival score for patients with metastatic spinal...
- 《Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer》 被引量: 104发表: 2009年 Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer Wakelee. (2014) Prolonged Survival of Patients With Non–Small-Cell Lung Cancer...
Non-small-cell lung cancerpostoperative radiotherapyprognostic factorssurvivalOBJECTIVES: To investigate the prognostic factors on survival in non-small-cell lung cancer patients treated with postoperative radiotherapy. METHODS: Sixty-five patients treated with a median dose of 59 Gy (50-66.6 Gy) between...
Results The median survival time of 1,742 patients was 10.0 months (9.5 months-10.5 months). One, two, three, four, and five-year survival rates were 44%, 22%, 13%, 9%, 6% respectively. The median survivals of single or multiple metastasis were...
l cell lung cancer) Survival not better with chemo for early NSCLC.(Pulmonary Medicine)(non-small cell lung cancer)Survival not better with chemo for early NSCLC.(Pulmonary Medicine)(non-small cell lung cancer)MacNeil, Jane Salodof
As one of the first studies testing perioperative anti-PD-(L)1 antibodies in resectable non-small-cell lung cancer (NSCLC), NADIM now confirms, in its final report, impressive 5-year clinical outcomes and that a pCR following neoadjuvant therapy translates into improved long-term survival. These...